Biocon's biologics arm gets regulatory approval in EU for Denosumab biosimilars
Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL, denosumab effectively inhibits the breakdown of bone, leading to increased bone mass and strength.
Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone.
Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults.
Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product.
The marketing authorisation follows a positive opinion issued by the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025.
Shreehas Tambe, CEO & managing director, Biocon Biologics, said: The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health.
In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region.
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.
The companys consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24.
The scrip shed 0.20% to currently trade at Rs 367.65 on the BSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
State looks at pvt players to boost goat meat export
Kolkata: The state animal resources development department is looking at investment from private players for processing meat of Black Bengal goat and boost its export in global markets. Tired of too many ads? go ad free now State animal resources development (ARD) minister Swapan Debnath on Thursday asked stakeholders in the meat industry to invest in development of processing units to promote Black Bengal goat in international markets. He was speaking at a business conclave on animal husbandries and fisheries organised by Merchants' Chamber of Commerce. Special secretary in the ARD department Abhijit Shevale said in Purulia's Jhalda, about 300 farmers, mostly women, are farming Black Bengal goats that have a huge potential for export. Debnath said: "The Black Bengal goat's meat has huge potential and we request the private sector to harvest it in other parts of the state. They can invest in the processing of this goat meat and help rural farmers with a global platform." In Bengal, the total sale of meat, especially of chicken and mutton, has increased from Rs 34 crore to Rs 106 crore over last year. The ARD department has also included pig meat recently through a Broiler Integrated Project taken up three years ago. West Bengal Livestock Development Corporation Ltd (WBLDCL) witnessed a turnover of Rs 1,600 crore last year. Utpal Kumar Karmakar, MD of WBLDCL, said: "We are giving the piglets to marginal farmers, especially women, for harvesting pig meat. We have started exporting pig meat from Alipurduar, Siliguri and Jalpaiguri to countries like Bhutan, Bahrain, Qatar through private players." Bengal has also started supplying fish like prawns, rohu and catla to Bihar, Jharkhand and Odisha, according to fisheries minister Biplab Roy Chowdhury. "In one year, we would be able to reduce our dependence on Andhra Pradesh for fish supply," he said.
NDTV
an hour ago
- NDTV
'Caution Not Anti-Science': Siddaramaiah On Covid Vaccine-Sudden Death Claim
New Delhi: Karnataka Chief Minister Siddaramaiah has responded to Biocon Ltd Executive Chairperson Kiran Mazumdar-Shaw's suggestion that he acknowledge the science behind vaccine development, rather than engage in retrospective blame. The chief minister shot back, "Seeking answers is not retrospective blame. It is the duty of a government that values every life." Siddaramaiah had fired the first shot with his post on X on July 1 that the state government ordered a study to find the reasons behind sudden deaths among young people in Karnataka, and whether Covid vaccines could have any role in them. This had prompted the reaction from the Biocon chief, who pointed out that the chief minister's claim that the vaccines were hastily approved was "factually incorrect and contributed to public misinformation". On Thursday, Siddaramaiah doubled down on his claim. "As Chief Minister, I have a duty to respond to the genuine concerns of people who have lost loved ones unexpectedly. When parents lose their young children or families lose breadwinners without warning, seeking clarity is not misinformation; it is an act of governance rooted in empathy," he said. "Scientific caution is not anti-science. Many peer-reviewed studies (such as Nature, Circulation, Journal of the American College of Cardiology) have discussed myocarditis and cardiac arrest risk, particularly among young adults post-vaccination. Publicly funded stakeholders must acknowledge both the benefits and the potential risks without fear or favour. "When I said 'hastily', it reflects the unprecedented speed of emergency rollouts globally without complete long-term data, acknowledged even by WHO and global regulatory agencies, who termed it a 'calculated risk' during a pandemic. Haste is not a sin when saving lives, but acknowledging potential unintended consequences is wisdom," Siddaramaiah said in a long post on X. As Chief Minister, I have a duty to respond to the genuine concerns of people who have lost loved ones unexpectedly. When parents lose their young children or families lose breadwinners without warning, seeking clarity is not misinformation; it is an act of governance rooted in... — Siddaramaiah (@siddaramaiah) July 3, 2025 On Wednesday, the Union Health Ministry dismissed the Karnataka chief minister's comment, saying extensive studies by the Indian Council of Medical Research (ICMR) and the All India Institute of Medical Sciences (AIIMS) have conclusively established no linkages between coronavirus vaccines and sudden deaths. Studies by the ICMR and the National Centre for Disease Control (NCDC) also affirm that Covid-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects, it said. Sudden cardiac deaths can result from a wide range of factors, including genetics, lifestyle, pre-existing conditions, and post-covid complications, the ministry had said in a statement.
NDTV
an hour ago
- NDTV
Will The EU Delay Enforcing Its AI Act?
With less than a month to go before parts of the European Union's AI Act come into force, companies are calling for a pause in the provisions and getting support from some politicians. Groups representing big U.S. tech companies such as Google owner Alphabet and Facebook owner Meta, and European companies such as Mistral and ASML have urged the European Commission to delay the AI Act by years. What Is The August 2 Deadline? Under the landmark act that was passed a year earlier after intense debate between EU countries, its provisions would come into effect in a staggered manner over several years. Some important provisions, including rules for general purpose AI (GPAI) models, are due to apply on August 2. GPAI, which includes foundation models like those made by Google, Mistral and OpenAI, will be subject to transparency requirements such as drawing up technical documentation, complying with EU copyright law and providing detailed summaries about the content used for algorithm training. The companies will also need to test for bias, toxicity, and robustness before launching. AI models classed as posing a systemic risk and high-impact GPAI will have to conduct model evaluations, assess and mitigate risks, conduct adversarial testing, report to the European Commission on serious incidents and provide information on their energy efficiency. Why Do Companies Want A Pause? For AI companies, the enforcement of the act means additional costs for compliance. And for ones that make AI models, the requirements are tougher. But companies are also unsure how to comply with the rules as there are no guidelines yet. The AI Code of Practice, a guidance document to help AI developers to comply with the act, missed its publication date of May 2. "To address the uncertainty this situation is creating, we urge the Commission to propose a two-year 'clock-stop' on the AI Act before key obligations enter into force," said an open letter published on Thursday by a group of 45 European companies. It also called for simplification of the new rules. Another concern is that the act may stifle innovation, particularly in Europe where companies have smaller compliance teams than their U.S. counterparts. Will It Be Postponed? The European Commission has not yet commented on whether it will postpone the enforcement of the new rules in August. However, EU tech chief Henna Virkkunen promised on Wednesday to publish the AI Code of Practice before next month. Some political leaders, such as Swedish Prime Minister Ulf Kristersson, have also called the AI rules "confusing" and asked the EU to pause the act. "A bold 'stop-the-clock' intervention is urgently needed to give AI developers and deployers legal certainty, as long as necessary standards remain unavailable or delayed," tech lobbying group CCIA Europe said. The European Commission did not respond immediately to requests for comment.
